Bruker Q3 Revenue Rises 1.6%; Non-GAAP EPS Increases 24.4%

Bruker reported Q3 2026 revenue of $874.0M, up 1.6% YoY, and non-GAAP EPS of $0.56, up 24.4%. GAAP results included a $174.5M goodwill impairment charge. The company reaffirmed FY2026 guidance for organic revenue growth and non-GAAP EPS, updating currency assumptions. Bruker Scientific Instruments saw strong bookings and backlog growth.

Original reporting
Published Nov 4, 2026, 12:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bruker Q3 Revenue Rises 1.6%; Non-GAAP EPS Increases 24.4% — source image
Decision brief

The 30-second read

$BRKRNeutralMed
01

Why it matters

Earnings release adds new data on revenue, margins, and guidance, influencing short‑term price action.

02

Market read

Quarterly earnings provide fresh information for traders; modest guidance may temper price moves.

03

What to watch

Backlog strength and book‑to‑bill above 1 suggest future upside if demand accelerates.

Relevance 7/10Novelty 8/10Timing: after-hours

Background

Bruker Corp (BRKR) reported Q3 2026 results, reaffirmed FY2026 guidance, and reorganized segments.

Company-level read

Ticker impact

$BRKRNeutralHigh confidence
Context

Q3 2026 earnings released with revenue up 1.6% YoY and non‑GAAP EPS up 24.4%, plus reaffirmed FY2026 guidance.

Expected impact

potential slight downside as investors price in modest revenue growth and GAAP loss

Evidence & confidence

First report of quarterly results and guidance; numbers are new and material for traders.

Market effects

Provides a modest view of scientific instruments sector growth, especially in academic and biotech markets.

U.S. academic market demand highlighted; limited broader regional effect.

Limited global impact; mainly relevant to investors in analytical instrumentation.

Counterpoint

Despite EPS beat, GAAP loss and low revenue growth could signal underlying weakness; consider short positions.

Key entities

  • Bruker Corp

    Scientific instruments manufacturer reporting Q3 results.

Related articles

$BRKRMed

Bruker Scientific Instruments BioSpin BSI Chemicals, Applied Markets, Life Sciences, In Vitro Diagnostics, Detection Bruker Energy & Supercon Technologies…

BRUKER CORP (BRKR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 As Reported As Recast Bruker Scientific Instruments ("BSI") BioSpin BSI Chemicals, Applied Markets, Life Sciences, In Vitro Diagnostics, Detection ("BSI CALID") BSI NANO Bruker Energy & Supercon Technologies ("BEST") Corporate Total BSI Biosystems ("BIOS") BSI Microb

$BRKRHighAI 8/10

Bruker Corp (BRKR) Q3 2026 Earnings Call Highlights: Margin Expansion and Strong

Bruker Corp (BRKR) reported Q3 2026 with 0.7% organic revenue growth, but significant margin expansion, with non-GAAP gross margin up 120 bps to 51.3% and operating margin up 400 bps to 16.3%. Non-GAAP EPS grew 24% year-over-year to $0.56. Bookings trends remained positive, with BSI book-to-bill above 1 for five quarters. However, semiconductor metrology and NMR faced pushouts, and a $175 million goodwill impairment charge was recorded.

$BRKRHighAI 9/10

Why is Bruker stock surging today?

Bruker (BRKR) stock rose 14.2% after reporting Q3 2026 earnings of $0.56 per share, beating estimates by 33%, with revenue at $874M. Non-GAAP operating margin expanded 400 bps to 16.3%. Jefferies raised its price target to $70. Management reconfirmed full-year EPS guidance of $2.10–$2.15. The stock hit a 52-week high of $68.98.

$BRKRMed

Bruker (BRKR) Q3 2026 Earnings Call Transcript

Bruker (BRKR) reported Q3 2026 revenues of $874M, up 1.6% YoY, with non-GAAP EPS of $0.56, up 24%. CEO Frank Laukien highlighted growth in U.S. academic/government, China, and semiconductor metrology markets. The company expects revenue acceleration and margin expansion, driven by strong bookings trends and strategic investments in AI and organ-on-a-chip technologies.

$BRKRMed

Bruker Corporation Q3 2026 Earnings Call Summary

Bruker Corporation reported Q3 2026 earnings with 400 basis points year-over-year non-GAAP operating margin expansion. The BSI segment had a book-to-bill ratio over one for five quarters, and China BSI organic bookings grew over 20%. Management reconfirmed full-year 2026 organic revenue growth of 1% to 2% and non-GAAP EPS of $2.10 to $2.15. They expect double-digit EPS growth and at least 100 basis points of further operating margin expansion for fiscal year 2027.